Altitudes for Caregivers

Summary

The objective of this study is to assess the acceptability and feasibility of Altitudes, a novel digital behavioral health and psychoeducational intervention for caregivers and supporters of individuals experiencing first episode psychosis. The investigators will evaluate acceptability and feasibility with up to 30 caregivers and supporters over the course of 6 months. Acceptability and usability will be assessed with various acceptability measures with the Altitudes caregivers and supporters, caregivers and supporters' engagement with the digital platform, and qualitative interviews with the Altitudes caregivers and supporters. The investigators will additional evaluate the impact of the platform on caregiver and supporter's psychological status, wellbeing, and social support, as measured via self-report questionnaires.

Conditions

• Care Burden
• Care Giving Burden
• Caregiver Burnout
• Caregiver Stress
• Caregiver Wellbeing
• Support, Family

Interventions

DEVICE

Altitudes USA

Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self-care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.

Sponsors & Collaborators

• North Carolina Department of Health and Human Services

  collaborator OTHER_GOV

• University of North Carolina, Chapel Hill

  lead OTHER

Principal Investigators

• David Penn, PhD · University of North Carolina, Chapel Hill

• Diana Perkins, MD, MPH · Univeristy of North Carolina, School of Medicine

• Kelsey Ludwig, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-01-15

Primary Completion

2024-11-01

Completion

2024-11-01

FDA Device

Yes

Countries

• United States

Study Locations